A quickie news roundup: ChatGPT for Clinicians unveiled, UHG to invest $1.5B in AI, Aidoc raises $150M, TriFetch raises $1.9M pre-seed, Boehringer Ingelheim & Eko Health partner on canine heart murmur detection

April 30, 2026 | by

Editor’s Note: Our thrice-weekly Alerts bring TTA stories to your mailbox. Generally Friday, Saturday (for weekenders) and Monday. Subscribe here if you’re not getting it! No spam, promotions, or list selling. And written 100% by a human–ask my fingers!)

ChatGPT moves from healthcare enterprises to the clinician level. This new version of OpenAI’s ChatGPT, ChatGPT for Clinicians, is designed to support clinical tasks like clinical search, documentation workflows, and deep medical research. It will be free for any verified physician, NP, PA, or pharmacist in the US, and is available now via their information page here. With its release, ChatGPT is also introducing HealthBench Professional, described as “an open benchmark for real clinician chat tasks across three use cases: care consult, writing and documentation, and medical research.” Release

ChatGPT for Healthcare was announced in January, but available to only a limited group of healthcare organizations.

UnitedHealth Group is having some better days. Last week on their earnings call, they announced that all units exceeded Q1 expectations. Their Q1 adjusted earnings per share (EPS) of $7.23 was well ahead of expectations, with total revenues of $111.7 billion, up 2% versus Q1 2025. Q1 membership fell slightly to 49.1 million from 49.8 million at the end of 2025. Their medical cost ratio (MCR) decreased to 83.9% from 84.8%, nearly a full point.

UHG is ‘on track’ to invest $1.5 billion in AI this year, especially at Optum with self-service digital scheduling that includes AI-enabled tools guiding patients “to the right appointment in the right setting at the right time”, plus increased digital access for members and providers with AI-enabled tools at UnitedHealth Care. 

UHG has been heavily criticized for its treatment of rural healthcare providers and hospitals. Timothy Noel, CEO of UnitedHealthcare Business, said that “We will accelerate payments in all lines of business by 50% for rural hospitals and exempt rural healthcare providers for most medical prior authorization requirements. And we are building network partnerships between rural providers and leading regional health systems.”  Let’s see if the good news stretches into Q2. Healthcare Finance News

Aidoc’s $150 million Series E brings their total funding to over $500 million. The AI-assisted clinical imaging system for radiology, cardiology, vascular and neurovascular healthcare teams is designed to help them find and triage injuries and other health conditions. It also integrates coordination software for stroke and cardiovascular care. The round for the NYC-based company was led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors and NVentures (NVIDIA’s venture capital arm). The fresh funds will be used to grow global presence and expand into other clinical areas. FDA clearance for its AI triage tool was gained in January. Mobihealthnews, Release 

TriFetch has a healthy pre-seed round. A $1.9 million pre-seed these days is rather unusual but TriFetch, an AI automation platform built for independent specialty clinics just emerging from stealth, nabbed it from Nexus Venture Partners, with participation from angels with backgrounds at Google, Hippocratic, Mercor, and MIT. TriFetch’s platform automates three workflows that dominate clinic operating costs (the “tri”): patient calls and scheduling, referral processing, and prior authorizations. It’s led by UCLA graduate computer science PhDs  and researchers Varuni Sarwal and Rosemary He. So far results seem impressive, with their pilots at California ophthalmology, cardiology, and gastroenterology clinics with results that save time and money. In one GI practice, with staff processing up to 100 referrals per day, TriFetch handled that workflow end to end, freeing roughly 16 hours of staff time daily, saving the clinic $200,000 per year.  Pulse 2.0/release

And for those who fetch for us, a diagnostic for heart murmurs. Boehringer Ingelheim, the German pharmaceutical company with a specialty in animal health, and Eko Health, a ‘reimagined’ stethoscope for heart and lung disease, partnered to develop a device and app to detect, visualize, and grade heart murmurs in dogs. This combines BI’s CANINEBEAT AI diagnostic algorithm, the Eko Vet+ app, and the Eko CORE Digital Attachment that connects to most single-tube stethoscopes.  Canine heart murmurs and cardiac disease are difficult to detect in early stages, where diagnosis and treatment can be most helpful. Availability of the combined technology through both BI and Eko has started in the US and UK, with Germany up next month. Additional markets will be phased in during 2026 and 2027.  Release 

Chutes & Ladders: Click Therapeutics raises $50M, lays off 27%; India’s IKS Health in talks to buy TruBridge for over $600M; TELCOR buys Sample for RCM expansion

April 15, 2026 | by

So far, not a lot of ups and downs this week….

What’s both a Ladder and a Chute?

Click Therapeutics put together a healthy Series D of $50 million to commercialize its digital therapeutic for the treatment of the experiential negative symptoms of schizophrenia. That’s a cheerful earful, except for the reported 27% of their employees who just got chuted with a pink slip. In the reported range of 100-250 employees, that means 27 to 67 employees being told ‘no work for you’ after bringing the company to the commercialization point. That is a deep cut.

Boehringer Ingelheim and Click jointly developed the digital technology, which received Breakthrough Device Designation by the FDA in 2024 as an investigational technology. It provides an an adjunct to standard antipsychotic therapy through interactive psychosocial intervention techniques.

With the $50 million funding, Boehringer turned over commercialization to Click. What is odd here is that companies with investigational tech and large partners usually keep the staff lean. Commercialization and funding then means that hires change from researchers to marketers, sales, and compliance, for a net gain. The next question is…when?

Austin Speier, chief strategy officer, commented to Behavioral Health Business: “While we are incredibly excited about the potential of CT-155, that shift means making hard changes to our team to match our new commercial mission. These were not decisions we made lightly, and we are deeply grateful to everyone who helped us reach this stage.” CT-155, as it is formally known, does not yet have FDA clearance. It has a Phase III study, CONVOKE (NCT05838625), a Phase III, multicenter, randomized, double-blind, 16-week study evaluating the efficacy and safety of CT-155 versus a digital control app. Neither the BHB and FierceBiotech articles nor Click’s release reveal a timeline for FDA clearance and marketing. Which means that final FDA approval may be more distant than the funding and turnover make it appear.

Indian RCM provider IKS Health seeks to add TruBridge’s RCM for $675 million. Talks are reportedly in an advanced stage with an all-cash offer funded by a $675 million debt facility from banks like Citi, Deutsche Bank, and JP Morgan. It covers both purchase price and refinances TruBridge’s existing debt. No formal offer has been tendered to TruBridge’s board or shareholders. Surprisingly, this has gained little notice in the US healthcare press.

TruBridge provides HIT, an EHR, and RCM for health systems and practices. It is both established from the late 1990s, when RCM was new, and fairly large–it serves 1,500 healthcare organizations and employs 3,500 people with revenue of $347 million. It IPO’d in 2002 as CPSI on Nasdaq, converting to TruBridge in 2024. IKS Health is HQ’d in Mumbai but has a US HQ in Texas. It has 13,350 employees and a global base of 600 clients. It’s public on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). In addition to RCM, it offers care coordination, risk and optimization, and utilization management tools for value-based care. Digital Health News (India)

Also in RCM, TELCOR is buying Sample Healthcare. Amount and transitions are undisclosed. Like TruBridge, TELCOR started in the late 1990s. It serves both hospital and independent labs’ RCM for billing plus point-of-care and laboratory data. It has a 57% market share in the US for point-of-care solutions and serves over 2,700 hospitals and laboratories. Sample will add an AI-driven workflow engine that will be marketed as a separate product. It received seed funding out of Y Combinator in 2024. It’s easy to determine that Sample is a tuck-in acquisition for TELCOR.  TELCOR release.